Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2

Nanobodies are 130 amino acid single-domain antibodies (V<sub>H</sub>H) derived from the unique heavy-chain-only subclass of Camelid immunogloblins. Their small molecular size, facile expression, high affinity and stability have combined to make them unique targeting reagents with numero...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Qilong Tang, Raymond J. Owens, James H. Naismith
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	COVID-19 antiviral therapy protein complexes single-chain antibodies Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/eb00c2bb5539434b893d93765492ab72
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:eb00c2bb5539434b893d93765492ab72
record_format	dspace
spelling	oai:doaj.org-article:eb00c2bb5539434b893d93765492ab722021-11-25T19:13:24ZStructural Biology of Nanobodies against the Spike Protein of SARS-CoV-210.3390/v131122141999-4915https://doaj.org/article/eb00c2bb5539434b893d93765492ab722021-11-01T00:00:00Zhttps://www.mdpi.com/1999-4915/13/11/2214https://doaj.org/toc/1999-4915Nanobodies are 130 amino acid single-domain antibodies (V<sub>H</sub>H) derived from the unique heavy-chain-only subclass of Camelid immunogloblins. Their small molecular size, facile expression, high affinity and stability have combined to make them unique targeting reagents with numerous applications in the biomedical sciences. The first nanobody agent has now entered the clinic as a treatment against a blood disorder. The spread of the SARS-CoV-2 virus has seen the global scientific endeavour work to accelerate the development of technologies to try to defeat a pandemic that has now killed over four million people. In a remarkably short period of time, multiple studies have reported nanobodies directed against the viral Spike protein. Several agents have been tested in culture and demonstrate potent neutralisation of the virus or pseudovirus. A few agents have completed animal trials with very encouraging results showing their potential for treating infection. Here, we discuss the structural features that guide the nanobody recognition of the receptor binding domain of the Spike protein of SARS-CoV-2.Qilong TangRaymond J. OwensJames H. NaismithMDPI AGarticleCOVID-19antiviral therapyprotein complexessingle-chain antibodiesMicrobiologyQR1-502ENViruses, Vol 13, Iss 2214, p 2214 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 antiviral therapy protein complexes single-chain antibodies Microbiology QR1-502
spellingShingle	COVID-19 antiviral therapy protein complexes single-chain antibodies Microbiology QR1-502 Qilong Tang Raymond J. Owens James H. Naismith Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2
description	Nanobodies are 130 amino acid single-domain antibodies (V<sub>H</sub>H) derived from the unique heavy-chain-only subclass of Camelid immunogloblins. Their small molecular size, facile expression, high affinity and stability have combined to make them unique targeting reagents with numerous applications in the biomedical sciences. The first nanobody agent has now entered the clinic as a treatment against a blood disorder. The spread of the SARS-CoV-2 virus has seen the global scientific endeavour work to accelerate the development of technologies to try to defeat a pandemic that has now killed over four million people. In a remarkably short period of time, multiple studies have reported nanobodies directed against the viral Spike protein. Several agents have been tested in culture and demonstrate potent neutralisation of the virus or pseudovirus. A few agents have completed animal trials with very encouraging results showing their potential for treating infection. Here, we discuss the structural features that guide the nanobody recognition of the receptor binding domain of the Spike protein of SARS-CoV-2.
format	article
author	Qilong Tang Raymond J. Owens James H. Naismith
author_facet	Qilong Tang Raymond J. Owens James H. Naismith
author_sort	Qilong Tang
title	Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2
title_short	Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2
title_full	Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2
title_fullStr	Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2
title_full_unstemmed	Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2
title_sort	structural biology of nanobodies against the spike protein of sars-cov-2
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/eb00c2bb5539434b893d93765492ab72
work_keys_str_mv	AT qilongtang structuralbiologyofnanobodiesagainstthespikeproteinofsarscov2 AT raymondjowens structuralbiologyofnanobodiesagainstthespikeproteinofsarscov2 AT jameshnaismith structuralbiologyofnanobodiesagainstthespikeproteinofsarscov2
_version_	1718410189560872960

Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2

Ejemplares similares